Pricing Log in Create free account

ADMA Biologics Inc (ADMA) vs Beam Therapeutics Inc. (BEAM)

ADMA Biologics Inc and Beam Therapeutics Inc. are both Biotechnology companies. ADMA Biologics Inc and Beam Therapeutics Inc. are of similar size ($2.6B and $2.4B). Beam Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; ADMA Biologics Inc trades at 14.8×. Beam Therapeutics Inc. grew revenue faster over the last twelve months: 158.9% against 8.04%. ADMA Biologics Inc has the higher net margin (33.0% vs −55.5%) and the higher return on invested capital (29.8% vs −1,599.3%). Across the 18 metrics below, ADMA Biologics Inc leads on 11 and Beam Therapeutics Inc. on 7.

Valuation

Metric ADMA BEAM Biotechnology median
P/E 14.83 n/m 8.50
P/S 4.76 15.69 9.71
P/B 5.97 2.29 2.13
Price to free cash flow 20.97 n/m 20.82
EV/EBITDA 10.74 n/m 0.64
EV/Sales 4.88 8.95 9.21
Earnings yield 6.74% (3.49%) (33.15%)
Free cash flow yield 4.77% (15.22%) (25.50%)

Profitability

Metric ADMA BEAM Biotechnology median
Gross margin 64.71% 100.00% 65.16%
Operating margin 43.82% (242.27%) 0.00%
Net margin 32.98% (55.45%) 0.00%
Free cash flow margin 22.69% (238.90%) 0.00%
Return on equity 41.90% (8.18%) (56.36%)
Return on assets 27.19% (6.23%) (48.04%)
Return on invested capital 29.78% (1,599.30%) 0.00%

Growth

Metric ADMA BEAM Biotechnology median
Revenue growth (TTM) 8.04% 158.88% 6.02%
EPS growth (last fiscal year) (25.93%) 82.31% 30.26%
Revenue growth, 5-year CAGR 64.60% 466.27% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADMA BEAM Biotechnology median
Debt to equity 0.49 0.09 0.00
Current ratio 6.97 14.57 4.72
Net debt to EBITDA (0.06) 3.30 0.96

Dividend

Metric ADMA BEAM Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADMA BEAM Biotechnology median
Market cap 2.40b 2.55b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack